Gilead Sciences, Inc. (FRA:GIS)

Market Cap	159.44B +33.7%
Revenue (ttm)	25.08B +2.4%
Net Income	7.25B +1,672.9%
EPS	5.77 +1,684.2%
Shares Out	n/a
PE Ratio	22.00
Forward PE	17.32
Dividend	2.76 (2.15%)
Ex-Dividend Date	Dec 15, 2025

Volume	590
Average Volume	563
Open	128.66
Previous Close	129.38
Day's Range	128.12 - 128.66
52-Week Range	82.61 - 132.00
Beta	n/a
RSI	64.63
Earnings Date	Feb 10, 2026

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1987
• Employees: 17,600
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: GIS

Financial Performance

In 2025, Gilead Sciences's revenue was $29.44 billion, an increase of 2.40% compared to the previous year's $28.75 billion. Earnings were $8.51 billion, an increase of 1672.92%.

Financial numbers in USD